Summary & Overview
HCPCS J9056: Bendamustine Hydrochloride Injection, 1 mg
HCPCS Level II code J9056 denotes a 1 mg unit of bendamustine hydrochloride (Vivimusta) for injection, used in oncology care for hematologic malignancies and certain solid tumor regimens. Nationally, accurate coding for chemotherapeutic agents like bendamustine is critical for appropriate claims processing, medication accounting, and clinical documentation. This publication reviews payer coverage landscapes and operational considerations for infusion drug billing.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9056 represents clinically and operationally, common sites of service where claims are generated, and which payers are included in the comparative discussion. The analysis highlights benchmarking elements commonly monitored for drug administration codes, notes on standard claim components, and policy-change areas that affect oncology drug billing and reimbursement. Practical takeaways include clarity on the code’s purpose, expected care settings, and the types of benchmarks and policy updates that influence coverage and payment for injected chemotherapeutic agents. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9056 describes an injection of bendamustine hydrochloride (Vivimusta), 1 mg. This code represents the billing unit for administration of the antineoplastic agent bendamustine when supplied for infusion or injection.
-
Service type: Intravenous or subcutaneous chemotherapeutic drug administration delivered as a single-agent antineoplastic medication.
-
Typical site of service: Oncology infusion centers, hospital outpatient infusion units, physician offices with chemotherapy services, and other outpatient infusion settings.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with relapsed indolent non-Hodgkin lymphoma presents to an outpatient oncology infusion center for systemic chemotherapy. The patient is scheduled to receive bendamustine hydrochloride (brand name Vivimusta) administered intravenously as part of a single-agent regimen or in combination with a monoclonal antibody. The workflow includes pre-infusion nursing assessment (vital signs, review of labs such as complete blood count and hepatic/renal function), verification of informed consent and allergies, pharmacy preparation and dose verification of J9056 (bendamustine hydrochloride, billed per 1 mg unit), infusion via peripheral IV or implanted port, nursing monitoring for infusion reactions, post-infusion observation and discharge instructions. Typical sites of service are the hospital outpatient infusion center, freestanding oncology infusion clinic, or physician office infusion suite. Common clinical scenarios include treatment of chronic lymphocytic leukemia, indolent B‑cell non-Hodgkin lymphoma, or relapsed/refractory lymphoma where bendamustine is medically indicated and dosed per body surface area with the drug billed using J9056 units corresponding to the total milligrams administered.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier reported |